Composition including stem cell-derived microvesicles for promoting neurogenesis
US-2015045298-A1 · Feb 12, 2015 · US
Pharmaceutical composition for treating cerebrovascular diseases, containing stem cell-derived exosome as active ingredient
US10167448B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10167448-B2 |
| Application number | US-201415103663-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 12, 2014 |
| Priority date | Dec 12, 2013 |
| Publication date | Jan 1, 2019 |
| Grant date | Jan 1, 2019 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to a pharmaceutical composition for treating cerebrovascular diseases including stem cell-derived exosomes as an active ingredient. The stem cell-derived exosomes according to the present invention have superior nerve cell protective effects, such as inhibition of cerebral ventricular distention, reduction of hydrocephalus, and inhibition of nerve cell death and cellular inflammation in an intraventricular hemorrhage (IVH) animal model, and thus, can be useful in treating cerebrovascular diseases including intraventricular hemorrhage, etc.
First claim
Opening claim text (preview).
What is claimed is: 1. A method for treating a cerebrovascular disease, comprising: administering to a subject having the cerebrovascular disease an effective amount of exosome derived from a stem cell, wherein the cerebrovascular disease is intraventricular hemorrhage (IVH), and wherein the stem cell is a mesenchymal stem cell. 2. The method according to claim 1 , wherein the mesenchymal stem cell is derived from one or more tissues selected from the group consisting of umbilical cord, cord blood, bone marrow, fat, muscle, nerve, skin, amnion, and placenta. 3. The method according to claim 1 , wherein the stem cell is treated with thrombin. 4. The method according to claim 1 , wherein the exosome is administered in a pharmaceutical composition containing a pharmaceutically acceptable carrier. 5. The method according to claim 4 , wherein the pharmaceutical composition is administered by injection or spray.
Assignees
Inventors
Classifications
Three-dimensional culture, tissue culture or organ culture; Encapsulated cells · CPC title
- C12N5/00Primary
Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor; (plant reproduction by tissue culture techniques A01H4/00) · CPC title
Artificially induced pluripotent stem cells, e.g. iPS · CPC title
Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells · CPC title
Drugs for disorders of the nervous system · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10167448B2 cover?
- The present invention relates to a pharmaceutical composition for treating cerebrovascular diseases including stem cell-derived exosomes as an active ingredient. The stem cell-derived exosomes according to the present invention have superior nerve cell protective effects, such as inhibition of cerebral ventricular distention, reduction of hydrocephalus, and inhibition of nerve cell death and ce…
- Who is the assignee on this patent?
- Samsung Life Public Welfare Foundation
- What technology area does this patent fall under?
- Primary CPC classification C12N5/00. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jan 01 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).